Biomarker analysis in the China cohort of the Phase 3 TALAPRO-2 trial of first-line talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC)

enzalutamide - Generic mfg.

Talzenna (talazoparib) - Pfizer

https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_1/print/presentation/3776

Hao Zeng; Hongqian Guo; Yong Yang; Xiaoping Zhang; Boxin Xue; Yong Wang; Junhui Jiang; Ting Sun; Wei Chen; Ben Wan; Dalin He; Qi Zhang; Hong Luo; Jianming Guo; Xiaolin Wang; Haihua Fu; Hongyu Ding; Ming Jiang; Xinying Su; Dingwei Ye

Jul 17, 2026